Evidence map›Paper›PMID 41251751›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2026

A potential drug target in epilepsy and its role in other neurological disorders.

Shang Gao, Yingjie Shen, Yongze Shen, Xiaofeng Fang, Wei Zhang, Yaolou Wang, Haopeng Zhang, Shanshan Yang, Hongsheng Liang

Abstract read
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Shang Gao *NHC Key Laboratory of Cell Transplantation, Department of Neurosurgery, The First Affiliated Hospital of Harbin Medical University, Heilongjiang Province, Harbin, 150001, People's Republic of China.
Yingjie Shen *NHC Key Laboratory of Cell Transplantation, Department of Neurosurgery, The First Affiliated Hospital of Harbin Medical University, Heilongjiang Province, Harbin, 150001, People's Republic of China.
Yongze ShenNHC Key Laboratory of Cell Transplantation, Department of Neurosurgery, The First Affiliated Hospital of Harbin Medical University, Heilongjiang Province, Harbin, 150001, People's Republic of China.
Xiaofeng FangNHC Key Laboratory of Cell Transplantation, Department of Neurosurgery, The First Affiliated Hospital of Harbin Medical University, Heilongjiang Province, Harbin, 150001, People's Republic of China.
Wei ZhangNHC Key Laboratory of Cell Transplantation, Department of Neurosurgery, The First Affiliated Hospital of Harbin Medical University, Heilongjiang Province, Harbin, 150001, People's Republic of China.
Yaolou WangNHC Key Laboratory of Cell Transplantation, Department of Neurosurgery, The First Affiliated Hospital of Harbin Medical University, Heilongjiang Province, Harbin, 150001, People's Republic of China.
Haopeng ZhangNHC Key Laboratory of Cell Transplantation, Department of Neurosurgery, The First Affiliated Hospital of Harbin Medical University, Heilongjiang Province, Harbin, 150001, People's Republic of China.
Shanshan YangDepartment of Neurology, The First Affiliated Hospital of Harbin Medical University, Heilongjiang Province, Harbin, 150001, People's Republic of China. yangshanshan81@hrbmu.edu.cn.
Hongsheng LiangNHC Key Laboratory of Cell Transplantation, Department of Neurosurgery, The First Affiliated Hospital of Harbin Medical University, Heilongjiang Province, Harbin, 150001, People's Republic of China. lianghongsheng@hrbmu.edu.cn.

Funding

National Natural Science Foundations of China No.82271340Natural Science Foundation of Heilongjiang Province No.PL2024H060Outstanding Youth Funding of Harbin Medical University No. HYD2020JQ0016
6 · The paper itself

Abstract

Epilepsy (EP) has an increased incidence due to several diseases, including neurodegenerative diseases and hemorrhagic stroke. The proteome-based research on developing suitable therapeutic interventions and disease prevention is beneficial. Cis-acting protein quantitative trait loci from 885 plasma and CSF proteins were used to explore potential drug targets for EP. After we got the preliminary association of TMEM106B with EP by drug target Mendelian randomization (MR), co-localization results identified TMEM106B as a potential drug target for EP further. The protein-protein interaction network indicated the interaction of proteins. Drug target MR and two-sample MR showed the role of TMEM106B in other 7 neurological diseases such as Alzheimer's disease (AD) and intracerebral hemorrhage (ICH). We included sensitivity tests, reverse MR, Steiger filtering, and phenotype scanning to strengthen our conclusion. We identified TMEM106B as a potential drug target for EP (P = 1.29 × 10

Indexed as

EpilepsyMembrane ProteinsNerve Tissue ProteinsNervous System DiseasesHumansMendelian Randomization AnalysisProtein Interaction MapsMembrane ProteinsNerve Tissue ProteinsTMEM106B protein, humanCausal associationDrug targetEpilepsyMendelian randomizationNeurological disordersTMEM106B

Identifiers

PMID41251751

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.